Saturday, October 31, 2026

Sole Focus on Gaming Eclipses VR Critical Use Cases: Virtuleap's Co-Founder

Elham P.Mohammadi

April 15, 2020

Amir Bozorgzadeh, Virtuleap's CEO, says the strong, one-sided focus on VR gaming overshadows the critical use cases of this technology. (Photo by Lux Interaction on Unsplash)

There has been such a massive hype around VR gaming in recent years that one cannot help but think of virtual reality as a technology primarily dedicated to gamers.

It is true that VR has for years been tipped to be the "next big thing" in the entertainment industry and that the world of gaming can take most of the credit for bringing immersive experiences closer to the mainstream.

However, as tech analyst Amir Bozorgzadeh argues, the strong, one-sided focus on the thrill of having a first-person perspective of game action could cast a dark shadow over critical use cases of VR, which are essential for the sustainable growth of the industry.

"I think a lot of the misconceptions about VR have to do with the fact that big players such as Oculus and HTC are focused so much on gaming, and gaming isn't often a critical use case of the technology in many cases," Amir, the CEO and co-founder of Virtuleap, a health and education VR startup, told Via News.

Amir Bozorgzadeh, Virtuleap's CEO, says many misconceptions about VR have to do with the fact that big players are focused so much on gaming. (Photo by Marc Mueller on Unsplash)
Amir Bozorgzadeh, Virtuleap's CEO, says many misconceptions about VR have to do with the fact that big players are focused so much on gaming. (Photo by Marc Mueller on Unsplash)

Referring to the recent media blitz surrounding Valve's newly released VR game Half-Life: Alyx, he said it is undeniable that great, spectacular games are being developed in a virtual environment.

"But it's been so much gaming, gaming, gaming, and gaming that many wrongly assume that the industry is gaming, and almost all media reports about whether VR is doing well or not doing well are about gaming, consumer, and entertainment. If they see that VR isn't interesting for entertainment, they say that it isn't doing well or isn't going to be a big thing."

The Lisbon-based entrepreneur calls it a "huge mistake" to put consumers and enterprises together because "they're so separate and are completely different industries."

"Even within enterprise, they're so different from each other in most cases," he said, adding that there are exceptions like Virtuleap, which is gamifying cognitive science with the help of VR and AI and operates in the intersection of education and healthcare at the same time.

Amir Bozorgzadeh, Virtuleap's co-founder and CEO (Photo by Cody Glenn/Web Summit via Sportsfile)
Amir Bozorgzadeh, Virtuleap's co-founder and CEO (Photo by Cody Glenn/Web Summit via Sportsfile)

Critical Use Cases

Amir says VR solutions are being successfully used to train people for high-danger, high-stress roles like those of pilots, surgeons, or those working in the architecture, engineering, and construction (AEC) industry.

"But they are not as fancy as the gaming and entertainment use cases so they don't get media coverage so easily. A lot of things are happening under the glacier in the VR industry, but many people do not know about them."

According to Virtuleap's CEO, one of the reasons behind this lack of market visibility is that those who are taking advantage of such use cases have active contracts with large companies such as Boeing or top automakers.

"But, on the gaming side, people are always wondering how many gamers will purchase their games. They constantly need media hype. They're so desperate for media hype, and, on the other side, the enterprise is so not desperate for media hype because it's all paid work."

It is a "huge mistake" to put consumer and enterprise together in the VR industry, according to Amir Bozorgzadeh, Virtuleap's CEO. (Photo by ThisIsEngineering on Pexels)
It is a "huge mistake" to put consumer and enterprise together in the VR industry, according to Amir Bozorgzadeh, Virtuleap's CEO. (Photo by ThisIsEngineering on Pexels)

So all the media attention goes toward the desperation side of things and that's based on a lot of "exaggerated claims", he added.

"We have to separate the two and understand that the entertainment industry isn't resting on solid ground. They're resting on shifting sand, and they know that."

FDA Support

Amir believes many people also do not realize that the Food and Drug Administration, a federal agency of the U.S. Department of Health and Human Services, is now supporting VR for healthcare use cases.  

"On March 5th, they had a really important meeting with many VR industry leaders where they discussed the use of VR for medical applications," he said, referring to a public workshop organized by the FDA.

According to the FDA, the event—entitled "Medical Extended Reality: Toward Best Evaluation Practices for Virtual and Augmented Reality in Medicine"—was held to identify critical gaps that may impede medical XR device development and innovative use of XR in medical applications.

The Food and Drug Administration, a federal agency of the U.S. Department of Health and Human Services, is now supporting VR for healthcare use cases.

Amir Bozorgzadeh, Virtuleap's co-founder and CEO

The co-founder of Virtuleap says initial studies have validated that VR can be used in certain cases as an alternative to opioid medication.

"It's been proven at that preliminary basis that the pain receptors in your brain are effectively dampened if you are in a VR simulation. It's not exactly known why or how this works. There's still a lot of research that has to be done, but experts know that pain reduction is one of the big use cases of VR."

He assumes that pain levels drop to certain degrees in a VR simulation because "the visual sense is the primary sense for a lot of people and when you create an alternative reality with a visual sense, it can trigger a lot of healthcare benefits like desensitizing you to social phobias or fear of heights or spiders."

It is huge in particular for the United States and the FDA because of the opioid crisis, he added.

(Photo credit: U.S. Centers for Disease Control and Prevention)
(Photo credit: U.S. Centers for Disease Control and Prevention)

U.S. Opioid Epidemic

Health experts say the U.S. is in the midst of an opioid epidemic. Findings of a national survey on drug use and health show that an estimated 10.3 million Americans aged 12 or older misused opioids in 2018, including 9.9 million prescription pain reliever misusers and 808,000 heroin users.

According to the U.S. Centers for Disease Control and Prevention, opioids were involved in 46,802 overdose deaths in 2018, accounting for 69.5% of all drug overdose deaths.

"There are hundreds of studies being done in the U.S. alone right now about the use of VR for medical purposes, but many people don't know that. Again it's a glacier thing. There's so much work in validation being done under the glacier that people don't understand how crazy big this industry is," Amir said.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com